05 DecAn investigational medication candidate in development for schizophrenia.

This is actually the initial demonstration of the efficacy of a variety of dosages of a long-acting injectable form of aripiprazole in a randomized scientific trial. The company remains on track to submit a New Drug Software to the U.S. Food and Drug Administration in the 3rd quarter of 2014. ‘With these compelling phase 3 data at hand, we are moving forward expeditiously to bring aripiprazole lauroxil to sufferers with schizophrenia and their families,’ said Serge Stankovic, M.D., MSPH, Senior Vice President, Clinical Medical and Advancement Affairs of Alkermes. ‘With a deep background in the development of long-performing injectable antipsychotic medicines, our researchers designed aripiprazole lauroxil rationally, in a ready-to-make use of format with multiple dosing choices, to meet the individual needs of patients and the doctors and nurses who treat them.’ Data from the entire analysis set of the phase 3 study showed: During the 12-week, double-blind treatment period, patients treated once-regular with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically and clinically significant placebo-adjusted indicate reductions from baseline in PANSS total scores .Northfelt, reviewed results of the Phase I study designed to evaluate the protection, tolerability and pharmacokinetics of ascending dosages of AEZS-112 in sufferers with the above-mentioned forms of cancer. Related StoriesCrucial modification in single DNA base predisposes children to intense form of cancerViralytics enters into scientific trial collaboration contract with MSDMeat-rich diet plan may increase kidney cancers riskIn part I, 22 patients were studied on 7 dose levels ranging from 13 to 800 mg/week. In all, 62 treatment cycles had been administered. In part II, 22 patients were studied on 5-dose levels which range from 120 to 600 mg/week. As of April 1, 2009, 62 treatment cycles were administered ; treatment was ongoing in 8 patients.